{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T22:45:28Z","timestamp":1781822728893,"version":"3.54.5"},"reference-count":10,"publisher":"Japan Endocrine Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1507\/endocrj.ej23-0256","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T22:15:05Z","timestamp":1698704105000},"page":"1195-1205","source":"Crossref","is-referenced-by-count":2,"title":["A retrospective study on tolvaptan prescription in clinical practice in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH) using the Japanese claims database"],"prefix":"10.1507","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4353-231X","authenticated-orcid":false,"given":"Daisuke","family":"Hagiwara","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2632-8808","authenticated-orcid":false,"given":"Miyuki","family":"Matsukawa","sequence":"additional","affiliation":[{"name":"Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo 101-8535, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Tasaki","sequence":"additional","affiliation":[{"name":"Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo 101-8535, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1285-4321","authenticated-orcid":false,"given":"Yumiko","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo 101-8535, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3746-1997","authenticated-orcid":false,"given":"Hiroshi","family":"Arima","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","unstructured":"1 The Japan Endocrine Society (2019) Guide for diagnosis and treatment of syndrome of inappropriate secretion of antidiuretic hormone (SIADH) (Revised 2019). Folia Endocrinologica Japonica 95 (Suppl May): 18\u201320 (In Japanese)."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Verbalis JG, Greenberg A, Burst V, Haymann JP, Johannsson G, et al. (2016) Diagnosing and treating the syndrome of inappropriate antidiuretic hormone secretion. Am J Med 129: 537.e9\u2013537.e23.","DOI":"10.1016\/j.amjmed.2015.11.005"},{"key":"3","unstructured":"3 Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, et al. (1998) OPC-41061, a highly potent human vasopressin V<sub>2<\/sub>-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 287: 860\u2013867."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Arima H, Goto K, Motozawa T, Mouri M, Watanabe R, et al. (2021) Open-label, multicenter, dose-titration study to determine the efficacy and safety of tolvaptan in Japanese patients with hyponatremia secondary to syndrome of inappropriate secretion of antidiuretic hormone. Endocr J 68: 17\u201329.","DOI":"10.1507\/endocrj.EJ20-0216"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Sterns RH, Riggs JE, Schochet SS Jr (1986) Osmotic demyelination syndrome following correction of hyponatremia. N Engl J Med 314: 1535\u20131542.","DOI":"10.1056\/NEJM198606123142402"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Brown WD (2000) Osmotic demyelination disorders: central pontine and extrapontine myelinolysis. Curr Opin Neurol 13: 691\u2013697.","DOI":"10.1097\/00019052-200012000-00014"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Singh TD, Fugate JE, Rabinstein AA (2014) Central pontine and extrapontine myelinolysis: a systematic review. Eur J Neurol 21: 1443\u20131450.","DOI":"10.1111\/ene.12571"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, et al. (2013) Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med 126: S1\u2013S42.","DOI":"10.1016\/j.amjmed.2013.07.006"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Kim Y, Lee N, Lee KE, Gwak HS (2020) Risk factors for sodium overcorrection in non-hypovolemic hyponatremia patients treated with tolvaptan. Eur J Clin Pharmacol 76: 723\u2013729.","DOI":"10.1007\/s00228-020-02848-6"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Castello LM, Baldrighi M, Panizza A, Bartoli E, Avanzi GC (2017) Efficacy and safety of two different tolvaptan doses in the treatment of hyponatremia in the emergency department. Intern Emerg Med 12: 993\u20131001.","DOI":"10.1007\/s11739-016-1508-5"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/70\/12\/70_EJ23-0256\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T04:06:18Z","timestamp":1703909178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/70\/12\/70_EJ23-0256\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej23-0256","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"EJ23-0256"}}